| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Testing | 91 | 2024 | 3531 | 7.550 |
Why?
|
| Genomics | 69 | 2024 | 5794 | 5.010 |
Why?
|
| Alzheimer Disease | 147 | 2023 | 8547 | 4.720 |
Why?
|
| Genetic Counseling | 31 | 2024 | 624 | 3.560 |
Why?
|
| Disclosure | 25 | 2022 | 738 | 3.410 |
Why?
|
| Genome, Human | 32 | 2024 | 4417 | 2.980 |
Why?
|
| Genetic Predisposition to Disease | 92 | 2024 | 17790 | 2.910 |
Why?
|
| Apolipoproteins E | 36 | 2018 | 1436 | 2.610 |
Why?
|
| Neonatal Screening | 18 | 2024 | 595 | 2.340 |
Why?
|
| Incidental Findings | 11 | 2018 | 698 | 2.210 |
Why?
|
| Apolipoprotein E4 | 23 | 2016 | 707 | 1.700 |
Why?
|
| Sequence Analysis, DNA | 18 | 2019 | 4713 | 1.550 |
Why?
|
| Biological Specimen Banks | 7 | 2021 | 783 | 1.370 |
Why?
|
| Genetics, Medical | 9 | 2023 | 336 | 1.350 |
Why?
|
| Genetic Privacy | 5 | 2018 | 60 | 1.330 |
Why?
|
| Health Knowledge, Attitudes, Practice | 22 | 2024 | 3986 | 1.290 |
Why?
|
| Genetic Diseases, Inborn | 5 | 2017 | 601 | 1.240 |
Why?
|
| Disease | 4 | 2021 | 671 | 1.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 14 | 2020 | 3616 | 1.210 |
Why?
|
| Parents | 19 | 2023 | 3549 | 1.180 |
Why?
|
| Family | 18 | 2021 | 3189 | 1.170 |
Why?
|
| Genetic Variation | 30 | 2021 | 6551 | 1.110 |
Why?
|
| Truth Disclosure | 8 | 2019 | 432 | 1.010 |
Why?
|
| Aminophylline | 2 | 2015 | 41 | 0.980 |
Why?
|
| Rare Diseases | 4 | 2023 | 619 | 0.970 |
Why?
|
| Genetic Research | 10 | 2021 | 172 | 0.970 |
Why?
|
| Sequence Analysis | 2 | 2015 | 240 | 0.930 |
Why?
|
| Chondroitinsulfatases | 1 | 2023 | 16 | 0.880 |
Why?
|
| Perception | 8 | 2018 | 1195 | 0.850 |
Why?
|
| Humans | 363 | 2024 | 760621 | 0.850 |
Why?
|
| Histocompatibility Testing | 2 | 2024 | 717 | 0.850 |
Why?
|
| Health Literacy | 2 | 2021 | 440 | 0.840 |
Why?
|
| Attitude to Health | 12 | 2019 | 2029 | 0.790 |
Why?
|
| Polymorphism, Single Nucleotide | 38 | 2024 | 15789 | 0.790 |
Why?
|
| Multifactorial Inheritance | 5 | 2024 | 1365 | 0.770 |
Why?
|
| Genotype | 43 | 2023 | 12960 | 0.770 |
Why?
|
| Cardiotonic Agents | 2 | 2015 | 546 | 0.760 |
Why?
|
| Research Subjects | 6 | 2018 | 249 | 0.720 |
Why?
|
| Male | 221 | 2024 | 359744 | 0.710 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2015 | 347 | 0.700 |
Why?
|
| Insurance, Long-Term Care | 3 | 2011 | 18 | 0.690 |
Why?
|
| Female | 221 | 2024 | 391270 | 0.690 |
Why?
|
| Aged, 80 and over | 99 | 2023 | 58995 | 0.680 |
Why?
|
| Cognition Disorders | 24 | 2016 | 3976 | 0.670 |
Why?
|
| Biomedical Research | 12 | 2021 | 3426 | 0.660 |
Why?
|
| HLA Antigens | 2 | 2024 | 1368 | 0.660 |
Why?
|
| Aged | 155 | 2024 | 169152 | 0.650 |
Why?
|
| Motivation | 15 | 2022 | 1993 | 0.630 |
Why?
|
| Penetrance | 3 | 2023 | 388 | 0.630 |
Why?
|
| Prenatal Diagnosis | 2 | 2023 | 1264 | 0.620 |
Why?
|
| Risk Assessment | 37 | 2024 | 24123 | 0.610 |
Why?
|
| Decision Making | 16 | 2022 | 3925 | 0.600 |
Why?
|
| Genome-Wide Association Study | 32 | 2024 | 12626 | 0.600 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 5 | 2021 | 380 | 0.590 |
Why?
|
| Middle Aged | 132 | 2024 | 220352 | 0.580 |
Why?
|
| Policy | 1 | 2021 | 511 | 0.580 |
Why?
|
| Neuropsychological Tests | 34 | 2014 | 7021 | 0.570 |
Why?
|
| Adult | 113 | 2024 | 219994 | 0.570 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2021 | 611 | 0.560 |
Why?
|
| Research | 2 | 2021 | 1974 | 0.520 |
Why?
|
| Attitude of Health Personnel | 7 | 2020 | 3865 | 0.520 |
Why?
|
| Adoption | 1 | 2016 | 97 | 0.510 |
Why?
|
| Ethics, Medical | 1 | 2021 | 783 | 0.510 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2023 | 1745 | 0.500 |
Why?
|
| Telephone | 2 | 2020 | 624 | 0.490 |
Why?
|
| Primary Health Care | 11 | 2023 | 4647 | 0.480 |
Why?
|
| Insurance Selection Bias | 1 | 2015 | 69 | 0.480 |
Why?
|
| Health Behavior | 11 | 2018 | 2622 | 0.480 |
Why?
|
| Prion Diseases | 1 | 2016 | 98 | 0.480 |
Why?
|
| Public Health | 5 | 2022 | 2653 | 0.470 |
Why?
|
| Cognition | 19 | 2020 | 6957 | 0.470 |
Why?
|
| Prions | 1 | 2016 | 179 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2024 | 10344 | 0.460 |
Why?
|
| Kidney Transplantation | 3 | 2024 | 4215 | 0.450 |
Why?
|
| Antigens, Human Platelet | 3 | 2019 | 41 | 0.450 |
Why?
|
| Memory | 4 | 2016 | 2179 | 0.440 |
Why?
|
| Infant, Newborn | 28 | 2024 | 26181 | 0.440 |
Why?
|
| Consumer Advocacy | 1 | 2014 | 81 | 0.440 |
Why?
|
| Insurance | 1 | 2015 | 114 | 0.440 |
Why?
|
| Hippocampus | 11 | 2017 | 3738 | 0.420 |
Why?
|
| Evidence-Based Practice | 2 | 2016 | 496 | 0.410 |
Why?
|
| Blood Group Antigens | 3 | 2019 | 187 | 0.410 |
Why?
|
| United States Food and Drug Administration | 5 | 2023 | 1677 | 0.410 |
Why?
|
| Mandatory Reporting | 1 | 2013 | 124 | 0.410 |
Why?
|
| Population Surveillance | 5 | 2020 | 2608 | 0.400 |
Why?
|
| Informed Consent | 8 | 2021 | 1005 | 0.400 |
Why?
|
| Amyloid beta-Peptides | 11 | 2023 | 3832 | 0.390 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 3696 | 0.390 |
Why?
|
| Etomidate | 1 | 2014 | 185 | 0.390 |
Why?
|
| Research Report | 1 | 2015 | 370 | 0.380 |
Why?
|
| Disease Progression | 27 | 2023 | 13502 | 0.380 |
Why?
|
| Risk Factors | 55 | 2024 | 74359 | 0.380 |
Why?
|
| Mental Recall | 4 | 2012 | 1206 | 0.380 |
Why?
|
| Patient Education as Topic | 8 | 2018 | 2315 | 0.370 |
Why?
|
| Anesthetics, Intravenous | 1 | 2014 | 397 | 0.370 |
Why?
|
| Brain | 28 | 2024 | 26951 | 0.370 |
Why?
|
| Physicians | 6 | 2023 | 4591 | 0.370 |
Why?
|
| Patient Preference | 7 | 2018 | 922 | 0.370 |
Why?
|
| Mass Screening | 6 | 2022 | 5423 | 0.370 |
Why?
|
| Family Health | 4 | 2010 | 1257 | 0.370 |
Why?
|
| Interinstitutional Relations | 1 | 2012 | 237 | 0.360 |
Why?
|
| Ethylene Glycols | 4 | 2018 | 190 | 0.360 |
Why?
|
| Longitudinal Studies | 23 | 2020 | 14495 | 0.360 |
Why?
|
| Flurbiprofen | 1 | 2009 | 21 | 0.350 |
Why?
|
| Attitude | 4 | 2023 | 777 | 0.350 |
Why?
|
| Mutation | 12 | 2023 | 29932 | 0.340 |
Why?
|
| Health Communication | 1 | 2013 | 212 | 0.340 |
Why?
|
| Academies and Institutes | 1 | 2012 | 319 | 0.330 |
Why?
|
| Information Dissemination | 5 | 2018 | 1131 | 0.330 |
Why?
|
| Pedigree | 10 | 2015 | 4578 | 0.330 |
Why?
|
| United States | 44 | 2023 | 72461 | 0.330 |
Why?
|
| Aging | 11 | 2015 | 8651 | 0.330 |
Why?
|
| Prescription Drugs | 1 | 2016 | 630 | 0.330 |
Why?
|
| Comprehension | 6 | 2018 | 618 | 0.320 |
Why?
|
| Self Disclosure | 1 | 2009 | 249 | 0.310 |
Why?
|
| Blood Grouping and Crossmatching | 2 | 2019 | 100 | 0.310 |
Why?
|
| Presenilins | 1 | 2008 | 53 | 0.310 |
Why?
|
| Employment | 1 | 2015 | 1112 | 0.310 |
Why?
|
| Age of Onset | 15 | 2019 | 3301 | 0.310 |
Why?
|
| Communication | 10 | 2021 | 3849 | 0.310 |
Why?
|
| Genetic Loci | 8 | 2020 | 2618 | 0.300 |
Why?
|
| Human Genome Project | 1 | 2008 | 199 | 0.300 |
Why?
|
| Government | 1 | 2008 | 160 | 0.300 |
Why?
|
| Postpartum Period | 1 | 2014 | 1167 | 0.300 |
Why?
|
| Ethylene Glycol | 1 | 2007 | 31 | 0.300 |
Why?
|
| Risk | 11 | 2016 | 9631 | 0.290 |
Why?
|
| Private Sector | 2 | 2011 | 397 | 0.290 |
Why?
|
| Civil Rights | 1 | 2008 | 131 | 0.290 |
Why?
|
| Algorithms | 7 | 2024 | 13981 | 0.290 |
Why?
|
| Methanol | 1 | 2007 | 91 | 0.290 |
Why?
|
| Young Adult | 31 | 2021 | 58741 | 0.280 |
Why?
|
| Antidotes | 1 | 2007 | 138 | 0.280 |
Why?
|
| Genome | 4 | 2022 | 1739 | 0.280 |
Why?
|
| Medical History Taking | 4 | 2018 | 773 | 0.270 |
Why?
|
| Fluorine Radioisotopes | 2 | 2018 | 413 | 0.270 |
Why?
|
| Pharmacogenetics | 7 | 2023 | 680 | 0.270 |
Why?
|
| Solvents | 1 | 2007 | 292 | 0.270 |
Why?
|
| Computational Biology | 7 | 2019 | 3505 | 0.270 |
Why?
|
| Dementia | 9 | 2012 | 2649 | 0.270 |
Why?
|
| Aniline Compounds | 4 | 2018 | 1069 | 0.270 |
Why?
|
| Intubation, Intratracheal | 1 | 2014 | 1328 | 0.260 |
Why?
|
| Cooperative Behavior | 2 | 2018 | 1500 | 0.260 |
Why?
|
| Adaptation, Psychological | 4 | 2013 | 2628 | 0.260 |
Why?
|
| Health Care Costs | 5 | 2019 | 3258 | 0.260 |
Why?
|
| Neoplasms | 6 | 2022 | 22072 | 0.260 |
Why?
|
| Pyrazoles | 4 | 2011 | 1999 | 0.260 |
Why?
|
| Personal Satisfaction | 5 | 2018 | 643 | 0.260 |
Why?
|
| Wounds and Injuries | 2 | 2019 | 2477 | 0.250 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2009 | 620 | 0.250 |
Why?
|
| Physicians, Primary Care | 3 | 2018 | 624 | 0.250 |
Why?
|
| Geriatric Assessment | 9 | 2013 | 1405 | 0.250 |
Why?
|
| Adult Children | 1 | 2005 | 103 | 0.250 |
Why?
|
| Physician-Patient Relations | 6 | 2018 | 3242 | 0.250 |
Why?
|
| Naproxen | 3 | 2011 | 100 | 0.240 |
Why?
|
| Prejudice | 1 | 2008 | 563 | 0.230 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2023 | 3334 | 0.230 |
Why?
|
| Cohort Studies | 25 | 2024 | 41335 | 0.230 |
Why?
|
| Research Design | 7 | 2014 | 6180 | 0.230 |
Why?
|
| Multicenter Studies as Topic | 5 | 2024 | 1722 | 0.220 |
Why?
|
| tau Proteins | 7 | 2023 | 2085 | 0.220 |
Why?
|
| Amino Acid Transport System y+L | 1 | 2023 | 17 | 0.220 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2019 | 571 | 0.220 |
Why?
|
| Cardiovascular Diseases | 8 | 2019 | 15757 | 0.220 |
Why?
|
| Phenotype | 15 | 2023 | 16546 | 0.210 |
Why?
|
| Bradycardia | 2 | 2015 | 299 | 0.210 |
Why?
|
| Fabry Disease | 1 | 2023 | 85 | 0.210 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2023 | 105 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3085 | 0.210 |
Why?
|
| Nova Scotia | 3 | 2019 | 34 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3205 | 0.200 |
Why?
|
| Professional-Patient Relations | 3 | 2017 | 726 | 0.200 |
Why?
|
| Factor Analysis, Statistical | 3 | 2021 | 998 | 0.200 |
Why?
|
| Apolipoprotein E3 | 4 | 2013 | 107 | 0.200 |
Why?
|
| Duty to Recontact | 1 | 2021 | 19 | 0.200 |
Why?
|
| Genetic Association Studies | 7 | 2021 | 2717 | 0.200 |
Why?
|
| Arthritis, Rheumatoid | 4 | 2018 | 3763 | 0.200 |
Why?
|
| Politics | 1 | 2008 | 814 | 0.200 |
Why?
|
| Antiporters | 1 | 2023 | 278 | 0.200 |
Why?
|
| National Human Genome Research Institute (U.S.) | 3 | 2016 | 22 | 0.200 |
Why?
|
| Health Education | 3 | 2018 | 1049 | 0.190 |
Why?
|
| Affect | 4 | 2013 | 1480 | 0.190 |
Why?
|
| Mental Status Schedule | 7 | 2011 | 314 | 0.190 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2023 | 440 | 0.190 |
Why?
|
| Stress, Psychological | 7 | 2019 | 4446 | 0.190 |
Why?
|
| Laboratories | 2 | 2016 | 462 | 0.180 |
Why?
|
| Access to Information | 2 | 2017 | 320 | 0.180 |
Why?
|
| Membrane Transport Proteins | 4 | 2015 | 1035 | 0.180 |
Why?
|
| Data Collection | 9 | 2014 | 3315 | 0.180 |
Why?
|
| MNSs Blood-Group System | 1 | 2020 | 7 | 0.180 |
Why?
|
| Educational Status | 9 | 2015 | 2515 | 0.180 |
Why?
|
| Clinical Trials as Topic | 8 | 2018 | 8056 | 0.180 |
Why?
|
| Reproducibility of Results | 13 | 2021 | 20080 | 0.180 |
Why?
|
| Gastritis | 1 | 2022 | 198 | 0.180 |
Why?
|
| HLA-A Antigens | 1 | 2020 | 225 | 0.180 |
Why?
|
| Fluid Therapy | 2 | 2016 | 579 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 7475 | 0.180 |
Why?
|
| HLA-DQ Antigens | 1 | 2020 | 211 | 0.180 |
Why?
|
| Amnesia | 2 | 2015 | 255 | 0.170 |
Why?
|
| Uncertainty | 4 | 2019 | 754 | 0.170 |
Why?
|
| Proxy | 2 | 2016 | 148 | 0.170 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 243 | 0.170 |
Why?
|
| Population Groups | 2 | 2022 | 211 | 0.170 |
Why?
|
| Clinical Medicine | 1 | 2021 | 145 | 0.170 |
Why?
|
| Executive Function | 2 | 2016 | 1374 | 0.170 |
Why?
|
| Child | 25 | 2022 | 79806 | 0.170 |
Why?
|
| HLA-B Antigens | 1 | 2020 | 331 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5325 | 0.160 |
Why?
|
| Colorectal Neoplasms | 4 | 2015 | 6853 | 0.160 |
Why?
|
| Databases as Topic | 2 | 2019 | 474 | 0.160 |
Why?
|
| Confidentiality | 4 | 2019 | 609 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2011 | 2282 | 0.160 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 3726 | 0.160 |
Why?
|
| Workflow | 2 | 2022 | 852 | 0.160 |
Why?
|
| HLA-DR Antigens | 1 | 2020 | 630 | 0.160 |
Why?
|
| Cholesterol, LDL | 2 | 2020 | 2420 | 0.160 |
Why?
|
| Primary Prevention | 1 | 2006 | 1207 | 0.160 |
Why?
|
| Insurance Coverage | 2 | 2021 | 1939 | 0.160 |
Why?
|
| Biotinidase | 1 | 2018 | 17 | 0.160 |
Why?
|
| Personal Autonomy | 3 | 2019 | 302 | 0.160 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2013 | 829 | 0.160 |
Why?
|
| Ambulances | 1 | 2019 | 92 | 0.160 |
Why?
|
| Traumatology | 1 | 2019 | 94 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2017 | 2895 | 0.160 |
Why?
|
| Aryldialkylphosphatase | 2 | 2010 | 63 | 0.160 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2019 | 763 | 0.150 |
Why?
|
| Graft Survival | 3 | 2024 | 3794 | 0.150 |
Why?
|
| Severity of Illness Index | 14 | 2020 | 15840 | 0.150 |
Why?
|
| Age Factors | 18 | 2019 | 18416 | 0.150 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2018 | 65 | 0.150 |
Why?
|
| Transportation of Patients | 1 | 2019 | 176 | 0.150 |
Why?
|
| Life Style | 6 | 2016 | 3896 | 0.150 |
Why?
|
| Organ Size | 6 | 2024 | 2254 | 0.150 |
Why?
|
| Research Personnel | 2 | 2013 | 582 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2023 | 12293 | 0.150 |
Why?
|
| Atrophy | 8 | 2015 | 1627 | 0.150 |
Why?
|
| Shock, Septic | 2 | 2016 | 761 | 0.150 |
Why?
|
| Genome, Mitochondrial | 1 | 2018 | 66 | 0.150 |
Why?
|
| Case-Control Studies | 17 | 2019 | 22053 | 0.150 |
Why?
|
| LDL-Receptor Related Proteins | 2 | 2008 | 118 | 0.150 |
Why?
|
| Patient Satisfaction | 4 | 2018 | 3448 | 0.140 |
Why?
|
| Cerebral Cortex | 4 | 2020 | 5761 | 0.140 |
Why?
|
| Forms and Records Control | 1 | 2018 | 158 | 0.140 |
Why?
|
| Genes, BRCA2 | 2 | 2019 | 603 | 0.140 |
Why?
|
| Information Storage and Retrieval | 1 | 2023 | 822 | 0.140 |
Why?
|
| Germ Cells | 1 | 2021 | 635 | 0.140 |
Why?
|
| Emotions | 4 | 2019 | 2734 | 0.140 |
Why?
|
| Phospholipase C gamma | 1 | 2017 | 130 | 0.140 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2012 | 448 | 0.140 |
Why?
|
| Multigene Family | 3 | 2011 | 1077 | 0.140 |
Why?
|
| Dietary Supplements | 1 | 2010 | 3392 | 0.140 |
Why?
|
| Activities of Daily Living | 4 | 2012 | 2417 | 0.140 |
Why?
|
| Adolescent | 24 | 2020 | 87810 | 0.140 |
Why?
|
| Multivariate Analysis | 6 | 2016 | 12159 | 0.140 |
Why?
|
| Attention | 2 | 2010 | 2387 | 0.140 |
Why?
|
| Trauma Centers | 2 | 2019 | 933 | 0.140 |
Why?
|
| Depression, Postpartum | 1 | 2021 | 345 | 0.140 |
Why?
|
| Health Personnel | 5 | 2023 | 3310 | 0.140 |
Why?
|
| Peptide Fragments | 4 | 2017 | 5125 | 0.140 |
Why?
|
| Follow-Up Studies | 14 | 2016 | 39261 | 0.140 |
Why?
|
| Software | 6 | 2019 | 4419 | 0.130 |
Why?
|
| Cardiomyopathies | 3 | 2019 | 1952 | 0.130 |
Why?
|
| Concept Formation | 2 | 2015 | 159 | 0.130 |
Why?
|
| Fetus | 1 | 2023 | 1859 | 0.130 |
Why?
|
| Retinitis Pigmentosa | 1 | 2020 | 397 | 0.130 |
Why?
|
| Metagenomics | 1 | 2019 | 457 | 0.130 |
Why?
|
| Sex Factors | 12 | 2019 | 10547 | 0.130 |
Why?
|
| Interleukin-1 Receptor Accessory Protein | 1 | 2015 | 5 | 0.130 |
Why?
|
| Newfoundland and Labrador | 2 | 2010 | 11 | 0.130 |
Why?
|
| Homozygote | 3 | 2015 | 1788 | 0.130 |
Why?
|
| Heterozygote | 7 | 2019 | 2798 | 0.130 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 1997 | 707 | 0.130 |
Why?
|
| Medical Informatics | 2 | 2014 | 732 | 0.130 |
Why?
|
| Alleles | 9 | 2018 | 6898 | 0.130 |
Why?
|
| ABO Blood-Group System | 1 | 2018 | 369 | 0.130 |
Why?
|
| Logistic Models | 9 | 2019 | 13314 | 0.130 |
Why?
|
| Prospective Studies | 14 | 2022 | 54303 | 0.130 |
Why?
|
| Health | 1 | 2019 | 396 | 0.130 |
Why?
|
| Internationality | 1 | 2021 | 1004 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2020 | 707 | 0.130 |
Why?
|
| Positron-Emission Tomography | 4 | 2018 | 6465 | 0.130 |
Why?
|
| Anxiety | 7 | 2019 | 4538 | 0.130 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2017 | 1311 | 0.130 |
Why?
|
| Infant | 8 | 2024 | 36060 | 0.120 |
Why?
|
| Erythrocytes | 3 | 2019 | 2415 | 0.120 |
Why?
|
| Depression | 8 | 2021 | 8044 | 0.120 |
Why?
|
| Pancreatitis | 1 | 2022 | 1100 | 0.120 |
Why?
|
| Gene Frequency | 6 | 2017 | 3615 | 0.120 |
Why?
|
| Sulfonamides | 3 | 2011 | 1977 | 0.120 |
Why?
|
| Regression Analysis | 7 | 2013 | 6360 | 0.120 |
Why?
|
| Neurology | 2 | 2010 | 779 | 0.120 |
Why?
|
| Behavioral Medicine | 1 | 1995 | 50 | 0.120 |
Why?
|
| Amyloid | 2 | 2021 | 842 | 0.120 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2016 | 238 | 0.120 |
Why?
|
| Cerebrovascular Disorders | 4 | 2015 | 1501 | 0.120 |
Why?
|
| Learning | 3 | 2010 | 1739 | 0.120 |
Why?
|
| Predictive Value of Tests | 13 | 2017 | 15289 | 0.120 |
Why?
|
| Early Diagnosis | 3 | 2015 | 1180 | 0.120 |
Why?
|
| Exons | 1 | 2020 | 2388 | 0.120 |
Why?
|
| Health Care Surveys | 4 | 2018 | 2435 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 5 | 2021 | 5508 | 0.110 |
Why?
|
| Genes, Dominant | 1 | 2016 | 863 | 0.110 |
Why?
|
| Coronary Artery Disease | 4 | 2019 | 6659 | 0.110 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2023 | 1164 | 0.110 |
Why?
|
| Information Seeking Behavior | 1 | 2015 | 116 | 0.110 |
Why?
|
| Drug Approval | 1 | 2021 | 816 | 0.110 |
Why?
|
| Butyrylcholinesterase | 1 | 2013 | 21 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2015 | 563 | 0.110 |
Why?
|
| Accidents, Traffic | 1 | 2019 | 814 | 0.110 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 1385 | 0.110 |
Why?
|
| Guidelines as Topic | 3 | 2016 | 1392 | 0.110 |
Why?
|
| Isoxazoles | 1 | 1995 | 230 | 0.110 |
Why?
|
| Military Personnel | 2 | 2020 | 1244 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1994 | 313 | 0.110 |
Why?
|
| Random Allocation | 2 | 2010 | 2394 | 0.110 |
Why?
|
| Botulinum Toxins | 1 | 1995 | 188 | 0.110 |
Why?
|
| Science | 1 | 2016 | 239 | 0.110 |
Why?
|
| Pancreatitis, Alcoholic | 1 | 2012 | 28 | 0.110 |
Why?
|
| Diagnostic Imaging | 4 | 2012 | 3527 | 0.110 |
Why?
|
| Odds Ratio | 7 | 2017 | 9716 | 0.110 |
Why?
|
| Public Policy | 1 | 2017 | 560 | 0.110 |
Why?
|
| Immunity | 1 | 2019 | 998 | 0.110 |
Why?
|
| Chromosome Mapping | 5 | 2021 | 4625 | 0.110 |
Why?
|
| Trypsinogen | 1 | 2012 | 84 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2020 | 3164 | 0.100 |
Why?
|
| Psychometrics | 2 | 2021 | 3051 | 0.100 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2012 | 238 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2018 | 3620 | 0.100 |
Why?
|
| Genes, BRCA1 | 2 | 2014 | 765 | 0.100 |
Why?
|
| Health Resources | 1 | 2019 | 935 | 0.100 |
Why?
|
| Radionuclide Imaging | 5 | 2016 | 1975 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2020 | 2668 | 0.100 |
Why?
|
| Twins, Dizygotic | 1 | 2013 | 236 | 0.100 |
Why?
|
| Presenilin-1 | 1 | 2016 | 660 | 0.100 |
Why?
|
| Calcineurin | 1 | 2013 | 229 | 0.100 |
Why?
|
| Valproic Acid | 1 | 1995 | 441 | 0.100 |
Why?
|
| Siblings | 3 | 2019 | 824 | 0.100 |
Why?
|
| Georgia | 4 | 2013 | 190 | 0.100 |
Why?
|
| Blood Preservation | 1 | 2012 | 168 | 0.100 |
Why?
|
| Claudins | 1 | 2012 | 115 | 0.100 |
Why?
|
| Trypsin | 1 | 2012 | 496 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 2 | 2019 | 2696 | 0.100 |
Why?
|
| Poly T | 1 | 2011 | 6 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2013 | 410 | 0.100 |
Why?
|
| Memory Disorders | 4 | 2014 | 1197 | 0.100 |
Why?
|
| Probability | 3 | 2016 | 2475 | 0.100 |
Why?
|
| Speech Perception | 1 | 1996 | 505 | 0.100 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2013 | 159 | 0.100 |
Why?
|
| Resuscitation | 1 | 2016 | 661 | 0.100 |
Why?
|
| Cephalometry | 2 | 2010 | 382 | 0.100 |
Why?
|
| Receptor, EphA1 | 1 | 2011 | 20 | 0.100 |
Why?
|
| Dystonia | 1 | 1995 | 364 | 0.100 |
Why?
|
| Interviews as Topic | 3 | 2013 | 2659 | 0.100 |
Why?
|
| Age Distribution | 4 | 2011 | 2893 | 0.100 |
Why?
|
| Polymorphism, Genetic | 4 | 2009 | 4291 | 0.100 |
Why?
|
| Depressive Disorder | 2 | 2007 | 3726 | 0.100 |
Why?
|
| Counseling | 2 | 2020 | 1548 | 0.090 |
Why?
|
| Blood Specimen Collection | 1 | 2012 | 238 | 0.090 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2011 | 195 | 0.090 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2015 | 1110 | 0.090 |
Why?
|
| Memantine | 1 | 2012 | 105 | 0.090 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2013 | 428 | 0.090 |
Why?
|
| Twins, Monozygotic | 1 | 2013 | 469 | 0.090 |
Why?
|
| Databases, Bibliographic | 3 | 2016 | 130 | 0.090 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2012 | 199 | 0.090 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 1411 | 0.090 |
Why?
|
| Medical Errors | 1 | 2019 | 1255 | 0.090 |
Why?
|
| New York City | 5 | 2012 | 724 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2020 | 36290 | 0.090 |
Why?
|
| DNA | 2 | 2021 | 7233 | 0.090 |
Why?
|
| Hospitalization | 6 | 2019 | 10790 | 0.090 |
Why?
|
| Molecular Typing | 1 | 2011 | 116 | 0.090 |
Why?
|
| Pyrrolidines | 1 | 1992 | 340 | 0.090 |
Why?
|
| Independent Living | 2 | 2011 | 570 | 0.090 |
Why?
|
| Plaque, Amyloid | 2 | 2013 | 758 | 0.090 |
Why?
|
| Caregivers | 3 | 2013 | 2224 | 0.090 |
Why?
|
| Urban Population | 2 | 2009 | 2022 | 0.090 |
Why?
|
| Drosophila melanogaster | 1 | 2019 | 1710 | 0.090 |
Why?
|
| Ethics Committees, Research | 1 | 2012 | 196 | 0.090 |
Why?
|
| Galactosemias | 1 | 2011 | 124 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2005 | 5075 | 0.090 |
Why?
|
| Pilot Projects | 8 | 2018 | 8555 | 0.090 |
Why?
|
| Assisted Living Facilities | 1 | 2010 | 26 | 0.090 |
Why?
|
| Founder Effect | 1 | 2010 | 186 | 0.090 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 3202 | 0.090 |
Why?
|
| Pregnancy | 4 | 2023 | 29749 | 0.090 |
Why?
|
| Patient-Centered Care | 3 | 2016 | 1416 | 0.090 |
Why?
|
| Waste Disposal, Fluid | 1 | 2009 | 31 | 0.090 |
Why?
|
| Influenza, Human | 2 | 2012 | 1528 | 0.080 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2011 | 282 | 0.080 |
Why?
|
| Personality | 1 | 2013 | 552 | 0.080 |
Why?
|
| Technology Transfer | 1 | 2009 | 42 | 0.080 |
Why?
|
| Linear Models | 5 | 2013 | 5877 | 0.080 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2012 | 448 | 0.080 |
Why?
|
| Canada | 4 | 2019 | 2128 | 0.080 |
Why?
|
| Publications | 1 | 2012 | 194 | 0.080 |
Why?
|
| Acetylcholinesterase | 1 | 1989 | 156 | 0.080 |
Why?
|
| Chromatin | 1 | 2021 | 2938 | 0.080 |
Why?
|
| Water Purification | 1 | 2009 | 58 | 0.080 |
Why?
|
| Patient Selection | 4 | 2018 | 4283 | 0.080 |
Why?
|
| Soil Pollutants | 1 | 2009 | 70 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 934 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2020 | 2165 | 0.080 |
Why?
|
| Databases, Genetic | 4 | 2018 | 1738 | 0.080 |
Why?
|
| Genetic Linkage | 1 | 1994 | 2381 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2013 | 6015 | 0.080 |
Why?
|
| Registries | 3 | 2019 | 8469 | 0.080 |
Why?
|
| Brain Chemistry | 1 | 2012 | 959 | 0.080 |
Why?
|
| Serum Albumin | 1 | 2011 | 674 | 0.080 |
Why?
|
| Microglia | 1 | 2017 | 1351 | 0.080 |
Why?
|
| Professional Practice | 1 | 2010 | 313 | 0.080 |
Why?
|
| Life Change Events | 1 | 2013 | 952 | 0.080 |
Why?
|
| Trail Making Test | 1 | 2008 | 57 | 0.080 |
Why?
|
| Washington | 1 | 2008 | 312 | 0.080 |
Why?
|
| Culture | 1 | 2012 | 622 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2020 | 10182 | 0.070 |
Why?
|
| Organizational Objectives | 1 | 2010 | 428 | 0.070 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2010 | 238 | 0.070 |
Why?
|
| Lipids | 1 | 2019 | 3336 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 3465 | 0.070 |
Why?
|
| Temporal Lobe | 3 | 2012 | 1688 | 0.070 |
Why?
|
| Piperidines | 2 | 1999 | 1650 | 0.070 |
Why?
|
| Prealbumin | 1 | 2009 | 222 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2020 | 4426 | 0.070 |
Why?
|
| Skilled Nursing Facilities | 1 | 2011 | 400 | 0.070 |
Why?
|
| Health Services for the Aged | 1 | 2010 | 259 | 0.070 |
Why?
|
| DNA Mismatch Repair | 1 | 2010 | 429 | 0.070 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2007 | 113 | 0.070 |
Why?
|
| Emergency Medicine | 1 | 2016 | 1196 | 0.070 |
Why?
|
| Family Relations | 1 | 2009 | 318 | 0.070 |
Why?
|
| Linkage Disequilibrium | 4 | 2017 | 1996 | 0.070 |
Why?
|
| Conflict of Interest | 1 | 2012 | 549 | 0.070 |
Why?
|
| Genetic Markers | 2 | 2008 | 2608 | 0.070 |
Why?
|
| Analysis of Variance | 6 | 2011 | 6238 | 0.070 |
Why?
|
| Microsatellite Instability | 1 | 2010 | 715 | 0.070 |
Why?
|
| Drug Industry | 1 | 2013 | 789 | 0.070 |
Why?
|
| Orientation | 2 | 2006 | 321 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 3707 | 0.070 |
Why?
|
| Cross-Cultural Comparison | 2 | 2006 | 633 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 1995 | 1116 | 0.070 |
Why?
|
| Massachusetts | 2 | 2017 | 8803 | 0.070 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 1109 | 0.070 |
Why?
|
| Endocrine Disruptors | 1 | 2009 | 263 | 0.070 |
Why?
|
| Double-Blind Method | 5 | 2011 | 12427 | 0.070 |
Why?
|
| Poisoning | 1 | 2007 | 252 | 0.070 |
Why?
|
| Benzodiazepines | 1 | 2012 | 1131 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 2011 | 5791 | 0.060 |
Why?
|
| Seizures | 2 | 2009 | 2917 | 0.060 |
Why?
|
| Mutation, Missense | 2 | 2015 | 2566 | 0.060 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 1989 | 387 | 0.060 |
Why?
|
| Prostatic Neoplasms | 4 | 2023 | 11345 | 0.060 |
Why?
|
| Water Pollutants, Chemical | 1 | 2009 | 354 | 0.060 |
Why?
|
| Behavior | 1 | 2008 | 540 | 0.060 |
Why?
|
| Psychomotor Agitation | 1 | 2008 | 305 | 0.060 |
Why?
|
| Injury Severity Score | 2 | 2019 | 1033 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 1 | 2011 | 1343 | 0.060 |
Why?
|
| Mental Processes | 1 | 2006 | 245 | 0.060 |
Why?
|
| Weight Loss | 1 | 2016 | 2686 | 0.060 |
Why?
|
| Prognosis | 4 | 2020 | 29658 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2017 | 3047 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 1547 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2010 | 1745 | 0.060 |
Why?
|
| Haplotypes | 3 | 2019 | 2764 | 0.060 |
Why?
|
| Reading | 1 | 2008 | 529 | 0.060 |
Why?
|
| Intention | 2 | 2018 | 345 | 0.060 |
Why?
|
| Demography | 3 | 2017 | 1650 | 0.060 |
Why?
|
| Individuality | 1 | 2006 | 300 | 0.060 |
Why?
|
| Community Health Services | 1 | 2010 | 654 | 0.060 |
Why?
|
| Social Stigma | 1 | 2011 | 734 | 0.060 |
Why?
|
| Utah | 3 | 2011 | 131 | 0.060 |
Why?
|
| Epilepsies, Partial | 1 | 1988 | 430 | 0.060 |
Why?
|
| Muscular Diseases | 2 | 2020 | 551 | 0.060 |
Why?
|
| Inservice Training | 2 | 2019 | 375 | 0.060 |
Why?
|
| Fatigue | 1 | 2011 | 1544 | 0.060 |
Why?
|
| Arabs | 1 | 2006 | 187 | 0.060 |
Why?
|
| Head | 1 | 2010 | 922 | 0.060 |
Why?
|
| Publishing | 1 | 2011 | 836 | 0.060 |
Why?
|
| Nerve Degeneration | 1 | 2008 | 748 | 0.060 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2007 | 540 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2015 | 2981 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2019 | 1067 | 0.060 |
Why?
|
| Altruism | 1 | 2005 | 205 | 0.060 |
Why?
|
| Health Status | 3 | 2013 | 4081 | 0.060 |
Why?
|
| Colonoscopy | 1 | 2011 | 1387 | 0.060 |
Why?
|
| Depressive Disorder, Major | 1 | 2021 | 4744 | 0.060 |
Why?
|
| Physician's Role | 1 | 2010 | 918 | 0.050 |
Why?
|
| Critical Care | 1 | 2016 | 2699 | 0.050 |
Why?
|
| Smoking | 3 | 2016 | 9073 | 0.050 |
Why?
|
| Time Factors | 8 | 2019 | 40165 | 0.050 |
Why?
|
| Heart Arrest | 1 | 2013 | 1506 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2006 | 704 | 0.050 |
Why?
|
| Medical Records | 1 | 2008 | 1407 | 0.050 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2020 | 919 | 0.050 |
Why?
|
| Cerebral Arteries | 1 | 2005 | 493 | 0.050 |
Why?
|
| Office Visits | 2 | 2017 | 597 | 0.050 |
Why?
|
| Reference Values | 5 | 2008 | 4925 | 0.050 |
Why?
|
| Obesity | 2 | 2016 | 12922 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 2622 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2008 | 1259 | 0.050 |
Why?
|
| Child of Impaired Parents | 1 | 2006 | 459 | 0.050 |
Why?
|
| Parkinson Disease | 3 | 2024 | 2859 | 0.050 |
Why?
|
| Visual Perception | 2 | 2012 | 1374 | 0.050 |
Why?
|
| Referral and Consultation | 2 | 2017 | 3598 | 0.050 |
Why?
|
| Pregnancy Complications | 2 | 2016 | 2942 | 0.050 |
Why?
|
| Brain Injuries | 1 | 2014 | 2044 | 0.050 |
Why?
|
| Sclerosis | 2 | 2014 | 210 | 0.050 |
Why?
|
| Ethics, Research | 2 | 2015 | 176 | 0.050 |
Why?
|
| Nursing Homes | 1 | 2010 | 1082 | 0.050 |
Why?
|
| Parent-Child Relations | 2 | 2021 | 758 | 0.050 |
Why?
|
| Sodium Chloride | 2 | 2016 | 591 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2010 | 1194 | 0.050 |
Why?
|
| Italy | 2 | 2019 | 841 | 0.050 |
Why?
|
| Personal Health Services | 2 | 2013 | 24 | 0.050 |
Why?
|
| Tissue Donors | 2 | 2022 | 2313 | 0.050 |
Why?
|
| Diet | 2 | 2017 | 8010 | 0.050 |
Why?
|
| Molecular Sequence Annotation | 2 | 2014 | 524 | 0.050 |
Why?
|
| Boston | 4 | 2020 | 9280 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2008 | 961 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2010 | 5785 | 0.050 |
Why?
|
| Sensitivity and Specificity | 5 | 2012 | 14660 | 0.050 |
Why?
|
| Retrospective Studies | 8 | 2023 | 80372 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2016 | 5990 | 0.050 |
Why?
|
| Ethanol | 1 | 2007 | 1323 | 0.050 |
Why?
|
| Length of Stay | 2 | 2014 | 6479 | 0.050 |
Why?
|
| Simvastatin | 1 | 2023 | 352 | 0.050 |
Why?
|
| Nootropic Agents | 2 | 2015 | 157 | 0.050 |
Why?
|
| Community Health Planning | 2 | 2012 | 166 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2014 | 3736 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2008 | 1266 | 0.040 |
Why?
|
| Exercise | 1 | 2017 | 5787 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2011 | 4000 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2010 | 2053 | 0.040 |
Why?
|
| Mood Disorders | 1 | 2007 | 1124 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2017 | 791 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 1758 | 0.040 |
Why?
|
| Veterans | 1 | 2014 | 2642 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8624 | 0.040 |
Why?
|
| Hospitals, Pediatric | 3 | 2014 | 1854 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 2890 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2008 | 1878 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2006 | 1341 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 5397 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2009 | 1940 | 0.040 |
Why?
|
| Gene Expression | 1 | 2012 | 7588 | 0.040 |
Why?
|
| Craniocerebral Trauma | 2 | 2003 | 491 | 0.040 |
Why?
|
| Confusion | 2 | 2012 | 279 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2020 | 400 | 0.040 |
Why?
|
| Drowning | 1 | 2019 | 26 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2021 | 8035 | 0.040 |
Why?
|
| Ribonuclease III | 1 | 2021 | 279 | 0.040 |
Why?
|
| Spouses | 2 | 2013 | 279 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2017 | 749 | 0.040 |
Why?
|
| Neurofibrillary Tangles | 2 | 2015 | 457 | 0.040 |
Why?
|
| Australia | 1 | 2022 | 1289 | 0.040 |
Why?
|
| Insurance, Health | 2 | 2008 | 2501 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2002 | 987 | 0.040 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2019 | 173 | 0.040 |
Why?
|
| Asphyxia | 1 | 2019 | 60 | 0.040 |
Why?
|
| Antipsychotic Agents | 1 | 2012 | 3061 | 0.040 |
Why?
|
| Cause of Death | 1 | 2009 | 3725 | 0.040 |
Why?
|
| Duty to Warn | 1 | 2018 | 30 | 0.040 |
Why?
|
| Arctic Regions | 1 | 1998 | 25 | 0.040 |
Why?
|
| Muscles | 1 | 2023 | 1581 | 0.040 |
Why?
|
| Models, Genetic | 4 | 2013 | 3442 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2020 | 349 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2010 | 3905 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2005 | 1206 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 3610 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2015 | 7850 | 0.040 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2021 | 383 | 0.040 |
Why?
|
| Internet | 3 | 2016 | 3078 | 0.040 |
Why?
|
| Child, Preschool | 6 | 2019 | 42063 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2007 | 1801 | 0.040 |
Why?
|
| Fires | 1 | 2019 | 169 | 0.040 |
Why?
|
| Harm Reduction | 1 | 2019 | 145 | 0.040 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 21025 | 0.040 |
Why?
|
| Health Policy | 1 | 2010 | 2677 | 0.040 |
Why?
|
| Galactosyltransferases | 1 | 2018 | 276 | 0.040 |
Why?
|
| Mental Disorders | 2 | 2013 | 6796 | 0.040 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2024 | 3701 | 0.040 |
Why?
|
| Socioeconomic Factors | 4 | 2014 | 7806 | 0.040 |
Why?
|
| Models, Psychological | 2 | 2015 | 827 | 0.040 |
Why?
|
| Hospitals | 2 | 2023 | 3928 | 0.030 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2017 | 92 | 0.030 |
Why?
|
| Genomic Structural Variation | 1 | 2017 | 63 | 0.030 |
Why?
|
| Friends | 1 | 2018 | 150 | 0.030 |
Why?
|
| Parenting | 1 | 2022 | 695 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 129 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2017 | 224 | 0.030 |
Why?
|
| Methionine Sulfoxide Reductases | 1 | 2017 | 76 | 0.030 |
Why?
|
| Plasma Substitutes | 1 | 2016 | 57 | 0.030 |
Why?
|
| Classification | 1 | 2017 | 127 | 0.030 |
Why?
|
| Tropicamide | 1 | 1996 | 22 | 0.030 |
Why?
|
| Cardiology Service, Hospital | 1 | 2018 | 242 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2017 | 313 | 0.030 |
Why?
|
| Colloids | 1 | 2016 | 122 | 0.030 |
Why?
|
| Medicaid | 1 | 2010 | 2815 | 0.030 |
Why?
|
| Isotonic Solutions | 1 | 2016 | 116 | 0.030 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2014 | 4555 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2010 | 4373 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2017 | 347 | 0.030 |
Why?
|
| Parasympatholytics | 1 | 1996 | 89 | 0.030 |
Why?
|
| Cardiology | 2 | 2018 | 1723 | 0.030 |
Why?
|
| Prevalence | 4 | 2018 | 15687 | 0.030 |
Why?
|
| Saudi Arabia | 1 | 2016 | 209 | 0.030 |
Why?
|
| Indiana | 1 | 2015 | 93 | 0.030 |
Why?
|
| Epilepsy | 1 | 2011 | 3267 | 0.030 |
Why?
|
| Minnesota | 1 | 2016 | 340 | 0.030 |
Why?
|
| Mediator Complex | 1 | 2015 | 106 | 0.030 |
Why?
|
| Brain Mapping | 3 | 2020 | 6568 | 0.030 |
Why?
|
| Pupil | 1 | 1996 | 141 | 0.030 |
Why?
|
| Chicago | 1 | 2015 | 244 | 0.030 |
Why?
|
| Placebo Effect | 1 | 1999 | 520 | 0.030 |
Why?
|
| Chlorpromazine | 1 | 1995 | 111 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 13262 | 0.030 |
Why?
|
| Comorbidity | 4 | 2016 | 10551 | 0.030 |
Why?
|
| Genetics | 1 | 2015 | 114 | 0.030 |
Why?
|
| Syndrome | 1 | 2021 | 3280 | 0.030 |
Why?
|
| Neck Muscles | 1 | 1995 | 100 | 0.030 |
Why?
|
| Amino Acids | 1 | 2020 | 1714 | 0.030 |
Why?
|
| Neurodegenerative Diseases | 2 | 2015 | 1084 | 0.030 |
Why?
|
| Phenytoin | 1 | 1995 | 188 | 0.030 |
Why?
|
| Phenylketonurias | 1 | 2015 | 123 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 587 | 0.030 |
Why?
|
| Tape Recording | 1 | 2013 | 75 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2019 | 1832 | 0.030 |
Why?
|
| Income | 1 | 2022 | 1875 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 1841 | 0.030 |
Why?
|
| Incidence | 5 | 2011 | 21392 | 0.030 |
Why?
|
| Putamen | 1 | 2015 | 291 | 0.030 |
Why?
|
| Social Class | 1 | 2003 | 2005 | 0.030 |
Why?
|
| Program Development | 2 | 2010 | 1297 | 0.030 |
Why?
|
| Acetamides | 1 | 2015 | 256 | 0.030 |
Why?
|
| Albumins | 1 | 2016 | 575 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2018 | 915 | 0.030 |
Why?
|
| Health Status Indicators | 2 | 2011 | 968 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2011 | 2932 | 0.030 |
Why?
|
| Caudate Nucleus | 1 | 2015 | 389 | 0.030 |
Why?
|
| Adenomatous Polyps | 1 | 1994 | 108 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 1677 | 0.030 |
Why?
|
| Cross-Sectional Studies | 4 | 2012 | 25942 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2013 | 123 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 2753 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2015 | 626 | 0.030 |
Why?
|
| Chromosomes | 1 | 2016 | 575 | 0.030 |
Why?
|
| Government Regulation | 1 | 2017 | 525 | 0.030 |
Why?
|
| Legislation as Topic | 1 | 2012 | 77 | 0.030 |
Why?
|
| Sex Characteristics | 2 | 2015 | 2629 | 0.030 |
Why?
|
| Risperidone | 1 | 1995 | 379 | 0.030 |
Why?
|
| Self-Injurious Behavior | 1 | 2019 | 554 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 221 | 0.030 |
Why?
|
| Binding Sites | 1 | 2021 | 6048 | 0.030 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2013 | 198 | 0.030 |
Why?
|
| Endophenotypes | 1 | 2014 | 255 | 0.030 |
Why?
|
| Overweight | 2 | 2014 | 2421 | 0.030 |
Why?
|
| Qualitative Research | 2 | 2017 | 2963 | 0.020 |
Why?
|
| Patients | 1 | 2018 | 906 | 0.020 |
Why?
|
| Social Marketing | 1 | 2011 | 52 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2014 | 956 | 0.020 |
Why?
|
| Proportional Hazards Models | 4 | 2011 | 12531 | 0.020 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2013 | 150 | 0.020 |
Why?
|
| Quality of Life | 1 | 2013 | 13308 | 0.020 |
Why?
|
| Sweden | 1 | 2015 | 1381 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 652 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 1077 | 0.020 |
Why?
|
| Cholesterol | 1 | 2020 | 2924 | 0.020 |
Why?
|
| Diabetes Mellitus | 2 | 2007 | 5889 | 0.020 |
Why?
|
| Acute Disease | 1 | 2022 | 7269 | 0.020 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2011 | 68 | 0.020 |
Why?
|
| Problem Solving | 1 | 1994 | 440 | 0.020 |
Why?
|
| Apolipoprotein E2 | 1 | 2011 | 135 | 0.020 |
Why?
|
| Tissue Banks | 1 | 2012 | 184 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 2015 | 1064 | 0.020 |
Why?
|
| Education | 1 | 2014 | 534 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2019 | 1056 | 0.020 |
Why?
|
| Antihypertensive Agents | 2 | 2013 | 2061 | 0.020 |
Why?
|
| Mothers | 1 | 2021 | 2186 | 0.020 |
Why?
|
| Monomeric Clathrin Assembly Proteins | 1 | 2010 | 24 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2011 | 2295 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 298 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 1902 | 0.020 |
Why?
|
| Americas | 1 | 2010 | 111 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2005 | 9287 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2013 | 1018 | 0.020 |
Why?
|
| Skull | 1 | 2015 | 815 | 0.020 |
Why?
|
| Directive Counseling | 1 | 2011 | 171 | 0.020 |
Why?
|
| Myocardial Infarction | 3 | 2008 | 11891 | 0.020 |
Why?
|
| Observation | 1 | 2012 | 312 | 0.020 |
Why?
|
| Poaceae | 1 | 2009 | 26 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2017 | 833 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2015 | 1112 | 0.020 |
Why?
|
| Survival | 1 | 2010 | 161 | 0.020 |
Why?
|
| Judgment | 1 | 2012 | 273 | 0.020 |
Why?
|
| Critical Illness | 1 | 2022 | 2709 | 0.020 |
Why?
|
| Biodegradation, Environmental | 1 | 2009 | 218 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2017 | 2208 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 3084 | 0.020 |
Why?
|
| Pregnancy, Multiple | 1 | 1990 | 215 | 0.020 |
Why?
|
| Oral Health | 1 | 2014 | 486 | 0.020 |
Why?
|
| Cerebral Decortication | 1 | 1988 | 11 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 1764 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 830 | 0.020 |
Why?
|
| Authorship | 1 | 2011 | 281 | 0.020 |
Why?
|
| Autopsy | 1 | 2012 | 1007 | 0.020 |
Why?
|
| Health Services Needs and Demand | 2 | 2006 | 1399 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1989 | 700 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2011 | 810 | 0.020 |
Why?
|
| Greece | 1 | 2009 | 336 | 0.020 |
Why?
|
| Coronary Artery Bypass | 2 | 2008 | 2272 | 0.020 |
Why?
|
| Sample Size | 1 | 2011 | 840 | 0.020 |
Why?
|
| Placebos | 1 | 1992 | 1668 | 0.020 |
Why?
|
| Religion | 1 | 2011 | 376 | 0.020 |
Why?
|
| Nerve Net | 1 | 2010 | 2261 | 0.020 |
Why?
|
| Psychosurgery | 1 | 1988 | 86 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 2019 | 2164 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2016 | 1992 | 0.020 |
Why?
|
| Telomere | 1 | 1994 | 933 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 568 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2013 | 1440 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2012 | 1218 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2010 | 499 | 0.020 |
Why?
|
| Marriage | 1 | 2009 | 350 | 0.020 |
Why?
|
| Protease Nexins | 1 | 2007 | 39 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2018 | 2520 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 1994 | 1420 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2010 | 367 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 1994 | 978 | 0.020 |
Why?
|
| Rural Population | 1 | 1998 | 2268 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 2864 | 0.020 |
Why?
|
| Patient Participation | 1 | 2016 | 1439 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 2698 | 0.020 |
Why?
|
| Germany | 1 | 2009 | 873 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 1754 | 0.020 |
Why?
|
| Denmark | 1 | 2009 | 760 | 0.020 |
Why?
|
| Physical Therapy Modalities | 1 | 2010 | 536 | 0.020 |
Why?
|
| Focus Groups | 1 | 2012 | 1378 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 9585 | 0.020 |
Why?
|
| Folic Acid | 1 | 2013 | 1309 | 0.020 |
Why?
|
| Cystic Fibrosis | 1 | 2015 | 1274 | 0.020 |
Why?
|
| Motor Activity | 1 | 2016 | 2687 | 0.020 |
Why?
|
| Commerce | 1 | 2011 | 605 | 0.020 |
Why?
|
| Macular Degeneration | 1 | 2013 | 1002 | 0.020 |
Why?
|
| Heart | 1 | 2019 | 4393 | 0.020 |
Why?
|
| Computer Simulation | 2 | 2016 | 6218 | 0.020 |
Why?
|
| Base Sequence | 1 | 2017 | 12446 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 1996 | 1647 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2018 | 15697 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 13451 | 0.020 |
Why?
|
| Stroke | 1 | 2008 | 9962 | 0.020 |
Why?
|
| Selection Bias | 1 | 2007 | 358 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2007 | 364 | 0.020 |
Why?
|
| Celiac Disease | 1 | 2013 | 822 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2019 | 5425 | 0.020 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2008 | 370 | 0.020 |
Why?
|
| Internal-External Control | 1 | 2006 | 359 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2016 | 2064 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2017 | 4938 | 0.010 |
Why?
|
| Israel | 1 | 2006 | 722 | 0.010 |
Why?
|
| Visual Cortex | 1 | 2012 | 1089 | 0.010 |
Why?
|
| Vesicular Transport Proteins | 1 | 2007 | 374 | 0.010 |
Why?
|
| Endosomes | 1 | 2007 | 519 | 0.010 |
Why?
|
| Acetaminophen | 1 | 2008 | 553 | 0.010 |
Why?
|
| Tissue and Organ Procurement | 1 | 2012 | 944 | 0.010 |
Why?
|
| Longevity | 1 | 2011 | 1050 | 0.010 |
Why?
|
| Introns | 1 | 2007 | 978 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 4407 | 0.010 |
Why?
|
| ROC Curve | 1 | 2012 | 3568 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 12965 | 0.010 |
Why?
|
| History, 21st Century | 1 | 2010 | 1575 | 0.010 |
Why?
|
| Observer Variation | 1 | 2010 | 2601 | 0.010 |
Why?
|
| International Cooperation | 1 | 2010 | 1433 | 0.010 |
Why?
|
| Angina Pectoris | 1 | 2007 | 969 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2015 | 3604 | 0.010 |
Why?
|
| Pyridines | 1 | 2015 | 2879 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 1889 | 0.010 |
Why?
|
| Corpus Callosum | 1 | 1988 | 749 | 0.010 |
Why?
|
| Autistic Disorder | 1 | 2013 | 1216 | 0.010 |
Why?
|
| Health Surveys | 1 | 2013 | 4063 | 0.010 |
Why?
|
| Brain Infarction | 1 | 2005 | 292 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2019 | 8525 | 0.010 |
Why?
|
| Models, Biological | 2 | 2010 | 9467 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2008 | 782 | 0.010 |
Why?
|
| Walking | 1 | 2010 | 1189 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 2852 | 0.010 |
Why?
|
| RNA | 1 | 2012 | 2722 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2007 | 1955 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 2013 | 2714 | 0.010 |
Why?
|
| Radiography | 1 | 2013 | 6965 | 0.010 |
Why?
|
| Atrial Fibrillation | 2 | 2013 | 5209 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 4878 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 1737 | 0.010 |
Why?
|
| Social Support | 1 | 2011 | 2145 | 0.010 |
Why?
|
| Emergency Service, Hospital | 2 | 2012 | 7818 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 2007 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 9411 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2011 | 2062 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2012 | 2698 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2011 | 5201 | 0.010 |
Why?
|
| Occupational Diseases | 1 | 2009 | 1486 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2007 | 2648 | 0.010 |
Why?
|
| Crohn Disease | 1 | 2013 | 2275 | 0.010 |
Why?
|
| Curriculum | 1 | 2014 | 3718 | 0.010 |
Why?
|
| Aphasia, Broca | 1 | 1980 | 52 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 2634 | 0.010 |
Why?
|
| Pediatrics | 1 | 2015 | 3586 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2007 | 1826 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2017 | 4775 | 0.010 |
Why?
|
| Causality | 1 | 2006 | 1242 | 0.010 |
Why?
|
| Western World | 1 | 1999 | 27 | 0.010 |
Why?
|
| Ginkgo biloba | 1 | 1999 | 26 | 0.010 |
Why?
|
| Self Report | 1 | 2011 | 3711 | 0.010 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2005 | 952 | 0.010 |
Why?
|
| Health Promotion | 1 | 2011 | 2206 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 6068 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 1990 | 2907 | 0.010 |
Why?
|
| Indans | 1 | 1999 | 91 | 0.010 |
Why?
|
| Plants, Medicinal | 1 | 1999 | 166 | 0.010 |
Why?
|
| Apoptosis | 1 | 2015 | 9501 | 0.010 |
Why?
|
| Aphasia | 1 | 1980 | 192 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2014 | 4783 | 0.010 |
Why?
|
| Mortality | 1 | 2009 | 2916 | 0.010 |
Why?
|
| Asia | 1 | 1999 | 620 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 16939 | 0.010 |
Why?
|
| Fear | 1 | 2006 | 1462 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2007 | 2825 | 0.010 |
Why?
|
| Poverty | 1 | 2009 | 2695 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 3340 | 0.010 |
Why?
|
| Phytotherapy | 1 | 1999 | 295 | 0.010 |
Why?
|
| Serial Learning | 1 | 1996 | 41 | 0.010 |
Why?
|
| Tacrine | 1 | 1996 | 4 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 1791 | 0.010 |
Why?
|
| Aspirin | 1 | 2008 | 3364 | 0.010 |
Why?
|
| Complementary Therapies | 1 | 1999 | 486 | 0.010 |
Why?
|
| Ophthalmic Solutions | 1 | 1996 | 304 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1995 | 5870 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 8950 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2010 | 3790 | 0.010 |
Why?
|
| Verbal Learning | 1 | 1996 | 462 | 0.010 |
Why?
|
| Survival Rate | 1 | 2007 | 12808 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 15620 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 11903 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2008 | 65017 | 0.010 |
Why?
|
| South Australia | 1 | 1990 | 26 | 0.010 |
Why?
|
| Macrophages | 1 | 2005 | 5745 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2003 | 4013 | 0.010 |
Why?
|
| Animals | 2 | 2019 | 167963 | 0.010 |
Why?
|
| Twins | 1 | 1990 | 339 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 1628 | 0.000 |
Why?
|
| Hypertension | 1 | 2007 | 8594 | 0.000 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1990 | 582 | 0.000 |
Why?
|
| Infant, Small for Gestational Age | 1 | 1990 | 460 | 0.000 |
Why?
|
| Speech Disorders | 1 | 1980 | 180 | 0.000 |
Why?
|
| Cerebral Infarction | 1 | 1980 | 982 | 0.000 |
Why?
|
| Functional Laterality | 1 | 1980 | 2253 | 0.000 |
Why?
|